Manipulation of host angioneogenesis

References

• Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265 - 273
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006; 91:986 - 998
   PubMed Web of Science ®Google Scholar
• Latgé JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12:310 - 350
   PubMed Web of Science ®Google Scholar
• Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Imun 2005; 73:494 - 503
   PubMed Web of Science ®Google Scholar
• Filler SG, Sheppard DC. Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2006; 2:129
   PubMed Web of Science ®Google Scholar
• Kamai Y, Chiang LY, Lopes Bezerra LM, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol 2006; 44:115 - 117
   Web of Science ®Google Scholar
• Lopes Bezerra LM, Filler SG. Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury and stimulation of tissue factor activity. Blood 2004; 103:2143 - 2149
   PubMed Web of Science ®Google Scholar
• Ferrara N, vis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4 - 25
   PubMed Web of Science ®Google Scholar
• Nilsson M, Heymach JV. Vascular endothelial growth factor (VEGF) pathway. J Thorac Oncol 2006; 1:768 - 770
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 2009; 114:5393 - 5399
   PubMed Web of Science ®Google Scholar
• Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009; 9:609 - 617
   PubMed Web of Science ®Google Scholar
• Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, Metzler LJ, et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog 2008; 4:1000200
   PubMed Web of Science ®Google Scholar
• Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol 2009; 1:S271 - S281
   Web of Science ®Google Scholar
• Kwon-Chung KJ, Sugui JA. What do we know about the role of gliotoxin in the pathobiology of Aspergillus fumigatus?. Med Mycol 2009; 1:97 - 103
   Web of Science ®Google Scholar
• Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47:226 - 235
   PubMed Web of Science ®Google Scholar
• Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555 - 557
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184 - 2191
   PubMed Web of Science ®Google Scholar
• Choe YS, Lee KH. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des 2007; 13:17 - 31
   PubMed Web of Science ®Google Scholar
• Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 2009; 335:205 - 222
   PubMed Web of Science ®Google Scholar
• Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006; 10:588 - 612
   PubMed Web of Science ®Google Scholar
• Ruegg C, Mutter N. Anti-angiogenic therapies in cancer: achievements and open questions. Bull Cancer 2007; 94:753 - 762
   PubMed Web of Science ®Google Scholar